Health Canada to review AstraZeneca’s COVID-19 prevention drug – National

AstraZeneca has asked Health Canada to review a new long-acting antibody combination that could be used to prevent symptomatic COVID-19.

If approved, it would be the first antibody protection of its kind in Canada.

Read more:
AstraZeneca COVID-19 drug prevents severe disease if given early, company says

The company says its clinical trials showed the antibody treatment was well tolerated and reduced the risk of developing symptomatic COVID-19 by 77 per cent compared to a placebo.

AstraZeneca Canada says it could be a good option for vulnerable populations who aren’t able to develop a strong protective response from a vaccine.

Click to play video: 'Health Canada considers Merck’s experimental COVID-19 drug'

Health Canada considers Merck’s experimental COVID-19 drug

Health Canada considers Merck’s experimental COVID-19 drug – Oct 4, 2021

The company says preliminary findings show the antibodies neutralize recent COVID-19 variants, including the Delta and Mu variants.

Story continues below advertisement

Health Canada has said all COVID-19 vaccine and drug submissions will be prioritized and reviewed on an expedited timeline.

Read more:
AstraZeneca seeks U.S. emergency approval for COVID-19 prevention drug

© 2021 The Canadian Press

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *